EG110A is a non-replicating HSV-1 vector designed to selectively silence the signals of type C sensory neurons responsible ...

Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced preliminary in ...

Dosed First Patient in REVEAL Pivotal Trial in the Fourth Quarter of 2025. Additional enrollment continues to advance across ...

When an exposure is exploited, the fallout spreads beyond the individual. Businesses, creators, investors, families, and even ...

The idea of the Instructed Retriever architecture is that it turns these implied conditions into explicit search parameters.

The operators behind the highly adaptable RondoDox botnet campaign that kicked off in late March have proven to be ready to embrace the latest attack trends. Most recently, in December they began ...

First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to Reached written alignment with FDA on inclusion of =3 months of safety data from ASPIRE trial evaluating TSHA-102 (N=3 ...

ActiveState, a global leader in open source language solutions and secure software supply chain management, today announced the release of its 2026 State of Vulnerability Management and Remediation ...

Rust-based inference engines and local runtimes have appeared with the shared goal: running models faster, safer and closer ...

Preliminary Preclinical Data Demonstrates In Vivo Proof-of-Concept for Novel Diabetes Gene Therapy in Type 2 Diabetic Non-Human Primates GPX-002 Rejuvenated Exhausted ...

In a world first, a team of researchers at the National Institutes of Health (NIH) and Emory School of Medicine, Atlanta, has ...

Despite multiple agencies being involved, the US could maintain a clear chain of command. This is something India should ...